145733-36-4

Basic information

• Product Name: Tasosartan
• Synonyms: TASOSARTAN;2,4-Dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one
• CAS NO: 145733-36-4
• Molecular Formula: C₂₃H₂₁N₇O
• Molecular Weight: 411.46
• Mol File: 145733-36-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 197-199°
• Boiling Point: 759.4 °C at 760 mmHg
• Flash Point: 413.1 °C
• Appearance: /
• Density: 1.328 g/cm³
• Vapor Pressure: 5.87E-23mmHg at 25°C
• Refractive Index: 1.665
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• PKA: 4.16±0.10(Predicted)
• CAS DataBase Reference: Tasosartan(CAS DataBase Reference)
• NIST Chemistry Reference: Tasosartan(145733-36-4)
• EPA Substance Registry System: Tasosartan(145733-36-4)

Safety Data

• Hazardous Substances Data: 145733-36-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 145733-36-4 differently. You can refer to the following data:
1. Antihypertensive.
2. Tasosartan is an angiotensin II receptor antagonist.

InChI:InChI=1/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)

Upstream product

• 153042-17-2 5,8-dihydro-2,4-dimethyl-8-<(2'-(2-tert-butyl-2H-tetrazol-5-yl)<1,1'-biphenyl>-4-yl)methyl>pyrido<2,3-d>pyrimidin-7(6H)-one 
• 149049-80-9 2,4-dimethyl-5,6,8-trihydro-8-[[2'-(1-tert-butyl-1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-7H-pyrido[2,3-d]pyrimidin-7-one 
• 145733-62-6 2,4-dimethyl-5,6,8-trihydro-8-[(4-bromophenyl)methyl]-7H-pyrido[2,3-d]pyrimidin-7-one 
• 22814-29-5 ethyl 3-(2,6-dimethyl-4-oxo-3H-pyrimidin-5-yl)propionate 
• 22814-39-7 ethyl 3-(4-chloro-2,6-dimethylpyrimidin-5-yl)propionate 
• 1501-06-0 diethyl 2-acetylglutarate 

Downstream Products

• 153042-14-9 2-methyl-7-oxo-8-<(2'-(1H-tetrazol-5-yl)<1,1'-biphenyl>-4-yl)methyl>-5,6,7,8-tetrahydropyrido<2,3-d>pyrimidine-4-carbaldehyde 
• 215437-28-8 (2S,3S,4S,5R,6R)-3,4,5-Triacetoxy-6-{5-[4'-(2,4-dimethyl-7-oxo-6,7-dihydro-5H-pyrido[2,3-d]pyrimidin-8-ylmethyl)-biphenyl-2-yl]-tetrazol-2-yl}-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 215437-29-9 (2S,3S,4S,5R,6R)-6-{5-[4'-(2,4-Dimethyl-7-oxo-6,7-dihydro-5H-pyrido[2,3-d]pyrimidin-8-ylmethyl)-biphenyl-2-yl]-tetrazol-2-yl}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid methyl ester 

Relevant articles and documents

Pyridopyrimidine Angiotensin II Antagonists

A series of pyridopyrimidine angiotensin II (A II) antagonists was synthesized and tested for antagonism of A II. Compounds with a biphenyltetrazole pharmacophore and small alkyl groups at the 2- and 4-positions of the pyridopyrimidine ring were found to be the most potent in an AT1 receptor binding assay and in blocking the A II pressor response in anesthetized, ganglion-blocked A II-infused rats. 5,8-Dihydro-2,4-dimethyl-8--4-yl)methyl>pyridopyrimidin-7(6H)-one (4a) was one of the more potent compounds in the binding assay and was the most efficacious compound in the A II-infused rat model. Further study of 4a in Goldblatt (2K-1C) rats showed the compound to have oral bioavailability and to be an efficacious and potent compound in a high renin form of hypertension.

SUBSTITUTED PYRRIDOPYRIMIDINES USEFUL AS ANGIOTENSIN II ANTAGONISTS

This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I STR1 useful for treating hypertension and congestive heart failure, to pharmaceutical compositions, and to methods for production thereof.